Physician profile
Neil Farbman
NPI 1861751364
$12,778.72
in general payments reported to CMS, 2019-2025
12 companies · $3,247 in 2025
The $3,247 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $179 · 2021: $272 · 2022: $8,124 · 2023: $534 · 2024: $423 · 2025: $3,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,475 · Food and Beverage: $1,703 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,475.00 |
| Food and Beverage | $1,702.98 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $10,633.09 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Alcon Vision LLC | $1,307.29 | 2020-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Johnson & Johnson Surgical Vision, INC. | $250.89 | 2021-2023 | Tecnis Iol, Tecnis Simplicity, Catalys System |
| Glaukos Corporation | $168.84 | 2022-2024 | Ce-Marked Kxla System |
| Harrow Eye, LLC | $87.38 | 2024-2025 | Vevye |
| Dompe US, INC. | $86.86 | 2022-2025 | Oxervate |
| Genentech USA, INC. | $77.18 | 2024-2025 | Vabysmo |
| Ani Pharmaceuticals, INC. | $53.29 | 2025 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $51.50 | 2020-2025 | |
| Abbvie INC. | $33.39 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $14.99 | 2025 | Envista Aspire Iol |
| Thea Pharma INC. | $14.02 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Farbman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.